Microscopic Polyangiitis Overview

Save information for later
Sign Up

Learn About Microscopic Polyangiitis

What is the definition of Microscopic Polyangiitis?
Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.
What are the alternative names for Microscopic Polyangiitis?
  • Microscopic polyangiitis
Who are the top Microscopic Polyangiitis Local Doctors?
Elite in Microscopic Polyangiitis
Dr. Peter A. Merkel
Rheumatology
Elite in Microscopic Polyangiitis
Dr. Peter A. Merkel
Rheumatology

Perelman Center For Advanced Medicine

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
215-662-2454
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Merkel is a Rheumatologist in Philadelphia, Pennsylvania. Dr. Merkel is rated as an Elite provider by MediFind in the treatment of Microscopic Polyangiitis. His top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Microscopic Polyangiitis, Takayasu Arteritis, and Tissue Biopsy. Dr. Merkel is currently accepting new patients.

Elite in Microscopic Polyangiitis
Dr. Paul A. Monach
Rheumatology
Elite in Microscopic Polyangiitis
Dr. Paul A. Monach
Rheumatology
150 S Huntington Ave, 
Boston, MA 
857-364-5552
Languages Spoken:
English
See accepted insurances

Paul Monach is a Rheumatologist in Boston, Massachusetts. Dr. Monach is rated as an Elite provider by MediFind in the treatment of Microscopic Polyangiitis. His top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Takayasu Arteritis, and Microscopic Polyangiitis.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Microscopic Polyangiitis
Xavier Puechal
Elite in Microscopic Polyangiitis
Xavier Puechal
Paris, FR 

Xavier Puechal practices in Paris, France. Mr. Puechal is rated as an Elite expert by MediFind in the treatment of Microscopic Polyangiitis. His top areas of expertise are Granulomatosis with Polyangiitis, Vasculitis, Necrotizing Vasculitis, Kidney Transplant, and Endoscopy.

View All Doctors
What are the latest Microscopic Polyangiitis Clinical Trials?
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis
Enrollment Status: Recruiting
Publish Date: September 30, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of rena...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective, Multicentric, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
A Prospective, Multicentric, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Phase: Not Applicable

Summary: Immunosuppressive therapy of granulomatosis with polyangiitis (GPA, Wegener's) and microscopic polyangiitis (MPA) has transformed the outcome from death to a strong likelihood of disease control and temporary remission. However, most patients have recurrent relapses that lead to damage and require repeated treatment associated with long-term morbidity and death. Rituximab has been shown to be as e...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center